April 27, 2020

Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment By Administering A Specific Spectrum Of UV-A Light Can Eradicate Viruses In Infected Human Cells

TDS = Trump Derangement Syndrome
Associated Press
Conference Call Scheduled for Tuesday, April 21, 2020 at 4:30 pm ET

ENGLEWOOD, CO / ACCESSWIRE / April 20, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the “Company”), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has signed an exclusive worldwide license from Cedars-Sinai to develop and commercialize the Healight Platform Technology (“Healight”). This medical device technology platform, discovered and developed by scientists at Cedars-Sinai, is being studied as a potential first-in-class treatment for coronavirus and other respiratory infections.

The company will host a live conference call and webcast Tuesday, April 21, 2020 at 4:30 p.m. ET. Conference call details are provided at the end of this press release.

Led by Mark Pimentel, MD, the research team of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai has been developing the patent-pending Healight platform since 2016 and has produced a growing body of scientific evidence demonstrating pre-clinical safety and effectiveness of the technology as an antiviral and antibacterial treatment. The Healight technology employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel endotracheal medical device. Pre-clinical findings indicate the technology’s significant impact on eradicating a wide range of viruses and bacteria, inclusive of coronavirus. The data have been the basis of discussions with the FDA for a near-term path to enable human use for the potential treatment of coronavirus in intubated patients in the intensive care unit (ICU). Beyond the initial pursuit of a coronavirus ICU indication, additional data suggest broader clinical applications for the technology across a range of viral and bacterial pathogens. This includes bacteria implicated in ventilator associated pneumonia (VAP).

“Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells,” stated Dr. Pimentel of Cedars-Sinai. Ali Rezaie, MD, one of the inventors of this technology states, “Our lab at Cedars-Sinai has extensively studied the effects of this unique technology on bacteria and viruses. Based on our findings we believe this therapeutic approach has the potential to significantly impact the high morbidity and mortality of coronavirus-infected patients and patients infected with other respiratory pathogens. We are looking forward to partnering with Aytu BioScience to move this technology forward for the benefit of patients all over the world.”

The company believes the Healight platform technology has the potential to positively impact outcomes for critically ill patients infected with coronavirus and severe respiratory infections. The company licensed exclusive worldwide rights to the technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. Patents have been filed by Cedars-Sinai Department of Technology Transfer, and Aytu BioScience will manage all aspects of intellectual property prosecution and filing globally. Aytu BioScience expects to partner the product outside the U.S.

“We are honored to be partnering with Cedars-Sinai as we believe the Healight therapeutic platform has the potential to help many patients during this coronavirus pandemic and beyond,” said Josh Disbrow, Chairman and CEO of Aytu BioScience.

The Company is engaging with the research team at Cedars-Sinai and the FDA to determine an expedited regulatory process to potentially enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.

Disbrow continued, “This first-in-class technology has the potential to be a game changer for clinicians treating patients infected with coronavirus and other respiratory conditions, and our team is working tirelessly alongside the Cedars-Sinai team to determine the safety and effectiveness of this device in humans.”
[source: NCBI US National Library of Medicine]
25.2.8. Conclusions Regarding Mechanisms

UBI has always caused much confusion, both in the general public and also in some medical professionals, because germicidal UV light (UVC) is used to sterilize water, disinfect surfaces, and as an aid to infection control in operating rooms, and food processing and packaging plants. Many people therefore assume that UBI must act by killing pathogens (bacteria, viruses or other microorganisms) circulating in the bloodstream. However there is no evidence that this is actually the case. Therefore the mechanisms of action must lie in some other action of UV on the various components of blood. Although the entire body of evidence on the mechanisms of action of UBI is very complex, as can be seen from the foregoing material, we can attempt to draw some general conclusions. Firstly UBI is clearly an example of the well-known phenomenon called “hormesis” or “biphasic dose response’. This phenomenon has been well reviewed by Edward Calabrese from U Mass Amherst [73, 74]. The basic concept states that any toxic chemical substance or drug, or any physical insult (such as ionizing radiation, hyperthermia, or oxidative stress) can be beneficial, protective or even therapeutic, provided the dose is low enough. If the dose is increased, the beneficial or protective effects disappear, and if the dose is even further increased, then the detrimental effects of the treatment become very evident. This is clearly shown by Knott’s original experiments on dogs that led to the establishment of only 5–7% of total blood volume as the optimal amount of blood to be irradiated.
๐Ÿ‘‡ This guy is founder of Occupy Democrats ๐Ÿ‘‡
UPDATE 4/27/20 at 6:32pm: Added info below.

No comments: